Autologous mesenchymal stem cell transplantation in stroke patients
Autologous mesenchymal stem cell transplantation in stroke patients
复制标题
DOI：
10.1002/ana.20501
复制
发表时间：
2005-06-01
影响因子：
11.2
通讯作者：
Lee, G
中科院分区：
文献类型：
--
作者：
Bang, OY;Lee, JS;Lee, G
间充质干细胞（MSC）移植改善动物缺血性中风的恢复。我们研究了使用培养扩增的自体间充质干细胞治疗缺血性卒中患者的可行性、有效性和安全性。我们前瞻性地随机将30例大脑中动脉区脑梗死和严重神经功能缺损的患者分为两个治疗组：MSC组（n = 5）接受静脉输注1 × 108自体MSC，而对照组（n = 25）不接受MSC。症状出现后1年，比较两组之间神经功能缺损的变化和功能的改善。每组5名患者连续进行神经影像学检查。与对照组患者相比，MSC治疗组患者的结局有所改善：Barthel指数（p = 0.011，0.017和0.017）。在随访期间，MSC组的改良兰金评分（3、6和12个月时分别为p = 0.076、0.171和0.286）持续改善。系列评价显示无细胞相关、血清学或成像定义的不良影响。在严重脑梗死患者中，静脉输注自体骨髓间充质干细胞似乎是一种可行且安全的治疗方法，可改善功能恢复。
Mesenchymal stem cell (MSC) transplantation improves recovery from ischemic stroke in animals. We examined the feasibility, efficacy, and safety of cell therapy using culture-expanded autologous MSCs in patients with ischemic stroke. We prospectively and randomly allocated 30 patients with cerebral infarcts within the middle cerebral arterial territory and with severe neurological deficits into one of two treatment groups: the MSC group (n = 5) received intravenous infusion of 1 X 108 autologous MSCs, whereas the control group (n = 25) did not receive MSCs. Changes in neurological deficits and improvements in function were compared between the groups for I year after symptom onset. Neuroimaging was performed serially in five patients from each group. Outcomes improved in MSC-treated patients compared with the control patients: the Barthel index (p = 0.011, 0.017, and 0. 115 at 3, 6, and 12 months, respectively) and modified Rankin score (p = 0.076, 0.171, and 0.286 at 3, 6, and 12 months, respectively) of the MSC group improved consistently during the follow-up period. Serial evaluations showed no adverse cell-related, serological, or imaging-defined effects. In patients with severe cerebral infarcts, the intravenous infusion of autologous MSCs appears to be a feasible and safe therapy that may improve functional recovery.